JP2937731B2 - Barium sulfate X-ray contrast agent with excellent long-term stability - Google Patents
Barium sulfate X-ray contrast agent with excellent long-term stabilityInfo
- Publication number
- JP2937731B2 JP2937731B2 JP5349106A JP34910693A JP2937731B2 JP 2937731 B2 JP2937731 B2 JP 2937731B2 JP 5349106 A JP5349106 A JP 5349106A JP 34910693 A JP34910693 A JP 34910693A JP 2937731 B2 JP2937731 B2 JP 2937731B2
- Authority
- JP
- Japan
- Prior art keywords
- barium sulfate
- ray contrast
- contrast agent
- cmc
- etherification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
【０００１】[0001]
【産業上の利用分野】本発明は、長期安定性の優れた硫
酸バリウムＸ線造影剤に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a barium sulfate X-ray contrast agent having excellent long-term stability .
【０００２】[0002]
【従来の技術】硫酸バリウムは化学的に非常に安定で且
つ無毒な化合物であり、強力なＸ線遮蔽作用を有するた
め、Ｘ線造影剤に広く使用されている。一般に硫酸バリ
ウムＸ線造影剤は、硫酸バリウム濃度が高く、流動性，
拡散性，付着性，耐酸性及び沈降安定性に優れ、服用し
易いこと等の条件が要求されるため、懸濁安定剤が必要
であり、トラガントガム，アラビアガム，コンドロイチ
ン硫酸，ペクチン，ポリアクリル酸塩，アルギン酸ナト
リウム，アルギン酸プロピレングリコール，カルボキシ
メチルセルロース等が単独又は併用して使用されてい
る。近年、硫酸バリウム濃度の高い造影剤が要望されて
おり、懸濁安定剤には沈降安定性の一層の改善が望まれ
ている。しかし、従来使用されて来た懸濁安定剤では流
動性，耐酸性などの性能を満足するものではあるが、長
期沈降安定性を完全に満足するものは見当たらず、粉末
製剤としての使用には耐え得るものの、懸濁液製剤とし
て充分性能を満足する懸濁安定剤は見当らないのが現状
である。2. Description of the Related Art Barium sulfate is a chemically very stable and non-toxic compound and has a strong X-ray shielding effect, and is therefore widely used as an X-ray contrast agent. Generally, barium sulfate X-ray contrast agents have a high barium sulfate concentration,
Diffusivity, adhesion, excellent acid resistance and sedimentation stability, since the conditions such that easily taken is required, it is necessary stabilizers cloudy suspension, tragacanth, gum arabic, chondroitin sulfate, pectins, polyacrylic acid Salts, sodium alginate, propylene glycol alginate, carboxymethyl cellulose and the like are used alone or in combination. In recent years, a contrast agent having a high barium sulfate concentration has been demanded, and further improvement in sedimentation stability has been desired for a suspension stabilizer. However, fluidity in suspension stabilizer came conventionally used, albeit intended to satisfy performance, such as acid resistance, not found is entirely satisfactory long-term sedimentation stability, for use as a powder formulation At present, there is no suspension stabilizer that can withstand, but sufficiently satisfies the performance as a suspension preparation.
【０００３】例えば、特公平４−７６９７５号公報に
は、硫酸バリウムＸ線造影剤の懸濁安定剤としてのエー
テル化度１．２５Ｍ／Ｃ６以上、且つ２％水溶液粘度が
２５℃で２０ｃｐｓ以下のカルボキシメチルセルロース
ナトリウム（以下、ＣＭＣと略す）を使用することが提
案されている。しかし、当該ＣＭＣを使用したＸ線造影
剤は流動性良好，耐酸性良好の特徴を有するものの、懸
濁液製剤に要求される長期沈降安定性に問題がある。更
に特開平１−２６１３３５号公報には、硫酸バリウムＸ
線造影剤の懸濁安定剤としてラムザンガム及び２％水溶
液粘度が２０ｃｐｓ以下であるＣＭＣを使用することが
提案されているが、低粘性，流動性良好，耐酸性良好の
特徴を有するものの、懸濁液製剤に要求される長期沈降
安定性に問題が残されている。For example, Japanese Patent Publication No. 4-76975 discloses that a barium sulfate X-ray contrast agent has a degree of etherification of 1.25 M / C 6 or more as a suspension stabilizer and a 2% aqueous solution viscosity of 20 cps or less at 25 ° C. It has been proposed to use sodium carboxymethylcellulose (hereinafter abbreviated as CMC). However, although the X-ray contrast agent using the CMC has characteristics of good flowability and good acid resistance, it has a problem in long-term sedimentation stability required for a suspension preparation. Further, JP-A-1-261335 discloses that barium sulfate X is used.
Although rhamsan and 2% aqueous solution viscosity as a suspension stabilizer lines contrast agents have been proposed to use a CMC or less 20 cps, low viscosity, fluidity good, although acid-resistant good characteristics, suspended Problems remain with the long-term sedimentation stability required for liquid formulations.
【０００４】[0004]
【発明が解決しようとする課題】本発明は、特に長期沈
降安定性に優れた硫酸バリウムＸ線造影剤を提供するこ
とを目的とするものである。SUMMARY OF THE INVENTION An object of the present invention is to provide a barium sulfate X-ray contrast agent which is particularly excellent in long-term sedimentation stability.
【０００５】[0005]
【課題を解決するための手段】本発明者等は上記課題に
鑑み、硫酸バリウムＸ線造影剤の懸濁安定剤としてＣＭ
Ｃに着目して鋭意研究を重ねた結果、２％水溶液粘度が
２５℃で２３ｃｐｓ以上２００ｃｐｓ以下で且つエーテ
ル化度が１．２５Ｍ／Ｃ６以上であるＣＭＣを懸濁安定
剤として、硫酸バリウムに対して１．０〜３．０ｗｔ％
添加することにより、飲用し易く、耐酸性，流動性，長
期沈降安定性に優れた硫酸バリウムＸ線造影剤が得られ
ることを見出し、本発明に到ったものである。SUMMARY OF THE INVENTION In view of the above problems, the present inventors have developed CM as a suspension stabilizer for barium sulfate X-ray contrast agents.
As a result of intensive studies focusing on C, barium sulfate was used as a suspension stabilizer for CMC having a 2% aqueous solution viscosity of 23 cps or more and 200 cps or less at 25 ° C. and a degree of etherification of 1.25 M / C 6 or more. 1.0-3.0 wt%
It has been found that by adding the same , a barium sulfate X-ray contrast agent which is easy to drink, and which is excellent in acid resistance, fluidity, and long-term sedimentation stability can be obtained.
【０００６】本発明に係る長期安定性の優れた硫酸バリ
ウムＸ線造影剤は、２５℃に於ける２％水溶液粘度が２
３ｃｐｓ以上２００ｃｐｓ以下で且つエーテル化度が
１．２５Ｍ／Ｃ６以上であるＣＭＣが懸濁安定剤とし
て、硫酸バリウムに対して１．０〜３．０ｗｔ％添加さ
れていることを特徴とするものである。ＣＭＣの２５℃
に於ける２％水溶液粘度が２３ｃｐｓ未満の場合は懸濁
液製剤に於ける長期沈降安定性が不充分であり、使用に
際し問題が生じ、２００ｃｐｓを超える場合は硫酸バリ
ウムゾルの粘度が高くなり流動性が悪くなり、飲用する
際に支障を来たす。また、ＣＭＣのエーテル化度が１．
２５Ｍ／Ｃ６未満の場合は耐酸性が不充分となり、胃酸
の作用を受けて凝固変化若しくは粘度上昇を起こして消
化管壁の状態を正確に造影し得なくなる。ＣＭＣの硫酸
バリウムに対する添加率が１．０ｗｔ％未満の場合は懸
濁液製剤に於ける長期沈降安定性及び耐酸性が低下し、
使用に際し問題が生じる。また、ＣＭＣの硫酸バリウム
に対する添加率が３．０ｗｔ％を超える場合は硫酸バリ
ウムゾルの粘度が高くなり懸濁液製剤の流動性が低下し
て飲用する際に支障を来たす。尚、本発明によれば、飲
用性，流動性，耐酸性も良好であり、粉末製剤としての
性能をも充分満足することは言うまでもない。[0006] Long-term stability of the high barium sulfate X-ray contrast media according to the present invention, 2 2% aqueous solution viscosity at the 25 ° C.
As CMC is a suspension stabilizer is and degree of etherification with 200cps inclusive 3cps is 1.25 M / C 6 or higher, 1.0~3.0wt% added with respect to barium sulfate
It is characterized by having been done. 25 ℃ of CMC
If 2% aqueous solution viscosity at is less than 2 3 cps is insufficient in long-term sedimentation stability in suspension formulations, there is a problem in use, sulfate burr when it exceeds 200cps
The viscosity of the umsol increases and the fluidity deteriorates, which hinders drinking. The degree of etherification of CMC is 1.
When it is less than 25M / C 6 becomes insufficient acid resistance, not obtained accurately image the state of the digestive tract wall causing coagulation changes or viscosity increase under the action of stomach acid. CMC sulfuric acid
If the addition ratio to barium is less than 1.0 wt %, the long-term sedimentation stability and acid resistance of the suspension formulation will decrease,
Problems arise when used. Also, barium sulfate of CMC
Addition ratios relative to three. If more than 0 wt %, sulfuric acid burr
The viscosity of the umsol increases and the fluidity of the suspension formulation decreases, which hinders drinking. According to the present invention, it is needless to say that the drinkability, fluidity, and acid resistance are good, and the performance as a powder preparation is sufficiently satisfied.
【０００７】[0007]
【実施例】以下、本発明を実施例によって詳細に説明す
るが、本発明はこれ等によって限定されるものではな
い。EXAMPLES The present invention will be described below in detail with reference to examples, but the present invention is not limited to these examples.
【０００８】実施例１ 水７１０ｇにＣＭＣ（２％水溶液粘度３３ｃｐｓ，エー
テル化度１．４０Ｍ／Ｃ６）を硫酸バリウムに対して
１．０ｗｔ％，２．０ｗｔ％となる量だけ溶解し、それ
に日局硫酸バリウム１３００ｇを添加して混合撹拌し、
１３０％（Ｗ／Ｖ）の硫酸バリウムゾルを得た。また、
参考例１として、水７１０ｇにＣＭＣ（２％水溶液粘度
３３ｃｐｓ，エーテル化度１．４０Ｍ／Ｃ ６ ）を硫酸バ
リウムに対して０．５ｗｔ％となる量だけ溶解し、それ
に日局硫酸バリウム１３００ｇを添加して混合撹拌し、
１３０％（Ｗ／Ｖ）の硫酸バリウムゾルを得た。 Example 1 CMC (2% aqueous solution viscosity 33 cps, degree of etherification 1.40 M / C 6 ) was added to 710 g of water with respect to barium sulfate.
Dissolve only 1.0 wt% and 2.0 wt%, add 1300 g of barium sulfate to Japan Pharmaceuticals, mix and stir,
A barium sulfate sol of 130% (W / V) was obtained. Also,
As Reference Example 1, CMC (2% aqueous solution viscosity
33 cps, degree of etherification 1.40 M / C 6 )
Dissolved in an amount of 0.5 wt% with respect to the lithium
Was added 1300 g of barium sulfate to Japan
A barium sulfate sol of 130% (W / V) was obtained.
【０００９】実施例２ 実施例１と同様にＣＭＣ（２％水溶液粘度２３ｃｐｓ，
エーテル化度１．４０Ｍ／Ｃ６）を硫酸バリウムに対し
て１．０ｗｔ％，３．０ｗｔ％となる量だけ溶解し、そ
れに日局硫酸バリウム１３００ｇを添加して混合撹拌
し、１３０％（Ｗ／Ｖ）の硫酸バリウムゾルを得た。ま
た、参考例２として、参考例１と同様にＣＭＣ（２％水
溶液粘度２３ｃｐｓ，エーテル化度１．４０Ｍ／Ｃ ６ ）
を硫酸バリウムに対して０．５ｗｔ％となる量だけ溶解
し、それに日局硫酸バリウム１３０ ０ｇを添加して混合
撹拌し、１３０％（Ｗ／Ｖ）の硫酸バリウムゾルを得
た。 Example 2 CMC (2% aqueous solution viscosity 23 cps,
The degree of etherification 1.40M / C 6) to barium sulfate
Then , 1300 g of barium sulfate was added thereto and mixed and stirred to obtain a barium sulfate sol of 130% (W / V). Ma
As Reference Example 2, CMC (2% water) was used in the same manner as Reference Example 1.
Solution viscosity 23cps, degree of etherification 1.40M / C 6 )
Dissolved in barium sulfate in an amount of 0.5 wt%
And add 1300 g of barium sulfate to the Japanese Pharmacopoeia and mix.
Stirring to obtain 130% (W / V) barium sulfate sol
Was.
【００１０】実施例３ 実施例１と同様にＣＭＣ（２％水溶液粘度２３ｃｐｓ，
エーテル化度１．２７Ｍ／Ｃ６）を硫酸バリウムに対し
て１．０ｗｔ％，３．０ｗｔ％となる量だけ溶解し、そ
れに日局硫酸バリウム１３００ｇを添加して混合撹拌
し、１３０％（Ｗ／Ｖ）の硫酸バリウムゾルを得た。ま
た、参考例３として、参考例１と同様に同様にＣＭＣ
（２％水溶液粘度２３ｃｐｓ，エーテル化度１．２７Ｍ
／Ｃ ６ ）を硫酸バリウムに対して０．５ｗｔ％となる量
だけ溶解し、それに日局硫酸バリウム１３００ｇを添加
して混合撹拌し、１３０％（Ｗ／Ｖ）の硫酸バリウムゾ
ルを得た。 Example 3 In the same manner as in Example 1, CMC (2% aqueous solution viscosity 23 cps,
The degree of etherification 1.27 M / C 6 ) with respect to barium sulfate
Then , 1300 g of barium sulfate was added thereto and mixed and stirred to obtain a barium sulfate sol of 130% (W / V). Ma
In addition, as Reference Example 3, CMC was used similarly to Reference Example 1.
(2% aqueous solution viscosity 23cps, degree of etherification 1.27M
/ C 6 ) in an amount of 0.5 wt% based on barium sulfate
Only, and add 1300 g of barium sulfate to JP
And agitate to obtain a 130% (W / V) barium sulfate.
I got
【００１１】実施例４ 実施例１と同様にＣＭＣ（２％水溶液粘度１５０ｃｐ
ｓ，エーテル化度１．４５Ｍ／Ｃ６）を硫酸バリウムに
対して１．０ｗｔ％，１．５ｗｔ％となる量だけ溶解
し、それに日局硫酸バリウム１３００ｇを添加して混合
撹拌し、１３０％（Ｗ／Ｖ）の硫酸バリウムゾルを得
た。また、参考例４として、参考例１と同様にＣＭＣ
（２％水溶液粘度１５０ｃｐｓ，エーテル化度１．４５
Ｍ／Ｃ ６ ）を硫酸バリウムに対して０．５ｗｔ％となる
量だけ溶解し、それに日局硫酸バリウム１３００ｇを添
加して混合撹拌し、１３０％（Ｗ／Ｖ）の硫酸バリウム
ゾルを得た。 Example 4 In the same manner as in Example 1, CMC (2% aqueous solution viscosity 150 cp)
s, degree of etherification 1.45M / C 6 ) to barium sulfate
On the other hand, only 1.0 wt% and 1.5 wt% of the barium sulfate were dissolved, and 1300 g of barium sulfate (JP) was added and mixed and stirred to obtain 130% (W / V) barium sulfate sol. Further, as Reference Example 4, CMC was used in the same manner as Reference Example 1.
(2% aqueous solution viscosity 150 cps, degree of etherification 1.45
M / C 6 ) becomes 0.5 wt% based on barium sulfate.
Dissolve only the amount and add 1300 g of barium sulfate
And mixed and stirred, and 130% (W / V) barium sulfate
A sol was obtained.
【００１２】参考例５ 実施例１と同様にＣＭＣ（２％水溶液粘度１４ｃｐｓ，
エーテル化度１．４０Ｍ／Ｃ６）を硫酸バリウムに対し
て０．５ｗｔ％，１．０ｗｔ％，３．０ｗｔ％となる量
だけ溶解し、それに日局硫酸バリウム１３００ｇを添加
して混合撹拌し、１３０％（Ｗ／Ｖ）の硫酸バリウムゾ
ルを得た。Reference Example 5 CMC (2% aqueous solution viscosity 14 cps,
The degree of etherification 1.40M / C 6) to barium sulfate
0.5wt%, 1.0wt%, 3.0wt%
Only dissolved, it Japanese Pharmacopoeia mixture was stirred by adding barium sulfate 1300 g, to obtain a sulfate Bariumuzoru of 130% (W / V).
【００１３】参考例６ 実施例１と同様にＣＭＣ（２％水溶液粘度２６ｃｐｓ，
エーテル化度１．００Ｍ／Ｃ６）を硫酸バリウムに対し
て０．５ｗｔ％，１．０ｗｔ％，３．０ｗｔ％となる量
だけ溶解し、それに日局硫酸バリウム１３００ｇを添加
して混合撹拌し、１３０％（Ｗ／Ｖ）の硫酸バリウムゾ
ルを得た。Reference Example 6 CMC (2% aqueous solution viscosity 26 cps,
The degree of etherification is 1.00 M / C 6 ) with respect to barium sulfate.
0.5wt%, 1.0wt%, 3.0wt%
Only dissolved, it Japanese Pharmacopoeia mixture was stirred by adding barium sulfate 1300 g, to obtain a sulfate Bariumuzoru of 130% (W / V).
【００１４】上記で得られた硫酸バリウムゾルを粘度測
定、耐酸性試験及び沈降試験に供試した。結果を表１に
示す。The barium sulfate sol obtained above was subjected to a viscosity measurement, an acid resistance test and a sedimentation test. Table 1 shows the results.
【００１５】粘度測定 Ｂ型粘度計（東京計器社製）で２５℃、６０ｒｐｍにて
測定した。 耐酸性試験 ガラス製試験管に人工胃液（ｐＨ１．１）３０ｍｌを入
れ、硫酸バリウムゾル１滴を滴下し、滴下直後及び３０
分放置後の状態を肉眼で観察し、凝固性を判定した。 （−）滴下と同時に煙状に分散し、液は均一に濃く白濁
する。 （±）極く弱い凝固を起こした数個の粒子が落下し、他
は（−）と同じ。 （＋）凝固した荒い粒子となって浮遊しながら分散し、
液は白濁する。 （＋＋）凝固を起こした多くの塊となって落下し、液は
透明。 （＋＋＋）滴下したままの塊で瞬間的に落下し、液は全
く濁らない。 沈降試験 硫酸バリウムゾルを１００ｍｌメスシリンダーに入れ、
１年間静置してその上澄液量（ｍｌ）を測定した。Viscosity measurement The viscosity was measured at 25 ° C. and 60 rpm using a B-type viscometer (manufactured by Tokyo Keiki Co., Ltd.). Acid resistance test 30 ml of artificial gastric juice (pH 1.1) was placed in a glass test tube, and 1 drop of barium sulfate sol was dropped.
The state after standing for a minute was visually observed to determine the coagulability. (-) At the same time as the dropping, it disperses in a smoke form, and the liquid becomes uniformly thick and cloudy. (±) Several particles with very weak coagulation fell down, otherwise the same as (-). (+) Coagulated coarse particles are dispersed while floating,
The solution becomes cloudy. (++) Drops as many solidified masses, and the liquid is transparent. (+++) Drops instantaneously in a lump that remains dropped, and the liquid is not turbid at all. Sedimentation test Barium sulfate sol was put into a 100 ml measuring cylinder,
After standing for one year, the amount of the supernatant (ml) was measured.
【００１６】[0016]
【表１】 [Table 1]
【００１７】[0017]
【発明の効果】長期沈降安定性に特に優れた硫酸バリウ
ムＸ線造影剤であって、耐酸性に優れ 、飲用性，流動性
もＸ線造影剤として要求される性能を満足するものであ
る。[Effect of the Invention A particularly good barium sulfate X-ray contrast media for long-term sedimentation stability, excellent acid resistance, drinking, fluidity
It is intended to satisfy the performance which is also required as X-ray contrast agent.
フロントページの続き (56)参考文献 特開 昭55−127322（ＪＰ，Ａ) 特開 昭52−76417（ＪＰ，Ａ) 特開 平１−261335（ＪＰ，Ａ) 特公 平４−76975（ＪＰ，Ｂ２) 米国特許3236735（ＵＳ，Ａ) (58)調査した分野(Int.Cl.6，ＤＢ名) A61K 49/04 A61K 9/107 A61K 47/38 ＣＡ（ＳＴＮ)Continuation of the front page (56) References JP-A-55-127322 (JP, A) JP-A-52-76417 (JP, A) JP-A-1-261335 (JP, A) JP-B-4-76975 (JP) U.S. Pat. No. 3,236,735 (US, A) (58) Fields investigated (Int. Cl. 6 , DB name) A61K 49/04 A61K 9/107 A61K 47/38 CA (STN)
Claims (1)
ｐｓ以上２００ｃｐｓ以下で且つエーテル化度が１．２
５Ｍ／Ｃ６以上であるカルボキシメチルセルロースナト
リウムが懸濁安定剤として、硫酸バリウムに対して１．
０〜３．０ｗｔ％添加されていることを特徴とする長期
安定性の優れた硫酸バリウムＸ線造影剤。1. The viscosity of a 2% aqueous solution at 25 ° C. is 23 c.
not less than ps to 200 cps and a degree of etherification of 1.2
As carboxymethylcellulose sodium suspension stabilizer is 5M / C 6 or higher, 1 for barium sulfate.
0 to 3.0 wt% added for long term
Barium sulfate X-ray contrast agent with excellent stability .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5349106A JP2937731B2 (en) | 1993-12-28 | 1993-12-28 | Barium sulfate X-ray contrast agent with excellent long-term stability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5349106A JP2937731B2 (en) | 1993-12-28 | 1993-12-28 | Barium sulfate X-ray contrast agent with excellent long-term stability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07196536A JPH07196536A (en) | 1995-08-01 |
| JP2937731B2 true JP2937731B2 (en) | 1999-08-23 |
Family
ID=18401535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5349106A Expired - Fee Related JP2937731B2 (en) | 1993-12-28 | 1993-12-28 | Barium sulfate X-ray contrast agent with excellent long-term stability |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2937731B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100665234B1 (en) * | 2005-07-27 | 2007-01-04 | 주식회사태준제약 | Peroral x-ray small bowel contrast media |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236735A (en) | 1962-09-14 | 1966-02-22 | Mallinckrodt Chemical Works | Barium sulfate and low viscosity monosaccharide polymer x-ray contrast media |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5276417A (en) * | 1975-12-22 | 1977-06-27 | Otsuka Pharma Co Ltd | Fluidifying method of balium sulfate |
| JPS55127322A (en) * | 1979-03-26 | 1980-10-02 | Otsuka Pharmaceut Factory Inc | Barium sulfate contrast medium for x-ray radiography |
| JPH01261335A (en) * | 1988-04-11 | 1989-10-18 | Dai Ichi Kogyo Seiyaku Co Ltd | Barium sulfate contrast medium for x ray |
| JP2689700B2 (en) * | 1990-07-18 | 1997-12-10 | 日本電気株式会社 | Laser oscillator |
-
1993
- 1993-12-28 JP JP5349106A patent/JP2937731B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236735A (en) | 1962-09-14 | 1966-02-22 | Mallinckrodt Chemical Works | Barium sulfate and low viscosity monosaccharide polymer x-ray contrast media |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07196536A (en) | 1995-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2847134B2 (en) | Ibuprofen composition for oral administration | |
| US5496563A (en) | Dry gel composition | |
| AU601206B2 (en) | Pharmaceutical formulations | |
| JPH09506605A (en) | Novel compositions for foams, especially rectal foams, and foams obtained therefrom | |
| KR20090073248A (en) | Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof | |
| US5338732A (en) | Megestrol acetate formulation | |
| CN106606476A (en) | Ibuprofen suspension drops and preparation method thereof | |
| US3236735A (en) | Barium sulfate and low viscosity monosaccharide polymer x-ray contrast media | |
| JP2002087922A (en) | Alginate impression material composition for dental use | |
| JP2937731B2 (en) | Barium sulfate X-ray contrast agent with excellent long-term stability | |
| TW528604B (en) | MCC: alginate pharmaceutical suspensions | |
| JP2814138B2 (en) | Suspension syrup | |
| JP3221737B2 (en) | Suspension composition for gastrointestinal contrast agent and contrast agent for gastrointestinal tract | |
| JP3717007B2 (en) | Novel barium powder formulation, ultra-high concentration barium suspension for upper gastrointestinal tract imaging using the same, and production method thereof | |
| JPH01261335A (en) | Barium sulfate contrast medium for x ray | |
| JPH0476975B2 (en) | ||
| JPH0314813B2 (en) | ||
| JP3765359B2 (en) | Stable APM suspension sweetener composition | |
| JPS61242548A (en) | Binder for feed for fish farming | |
| JPH0516405B2 (en) | ||
| FR2569564A1 (en) | Method for the stabilisation of a contrast product comprising barium sulphate, and product resulting therefrom | |
| JPH07196481A (en) | Base material for cataplasm agent | |
| Alam et al. | Rheological studies of chloramphenicol in sodium carboxymethyl cellulose suspensions | |
| JP2002532439A (en) | MRI contrast agent | |
| JPS62149793A (en) | Solid fuel-water slurry composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080611 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090611 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090611 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100611 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100611 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110611 Year of fee payment: 12 |
|
| LAPS | Cancellation because of no payment of annual fees |